Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
FRONTEO’s AI Engine Can Help Unearth Drug Targets, Predict Odds of Success: CTO
The advent of AI that leverages natural language processing might offer a breakthrough in efforts to identify novel targets for new drug development. Tokyo startup FRONTEO says its AI engine can uncover uncharted scientific connections hidden in research papers, enabling…
To read the full story
Related Article
- FRONTEO Expects First US User of KIBIT AI Engine This Year: CEO
July 24, 2026
- FRONTEO Opens AI Drug Discovery Lab, Pivots to Out-Licensing Model
May 15, 2026
- FRONTEO, Science Tokyo Roll Out AI Drug Discovery Hub
April 28, 2026
- Fronteo, Astellas Partner on AI-Driven Drug Target Discovery
April 20, 2026
- FRONTEO to Back Biotech Startups with AI and Capital as Third Biz Leg
February 13, 2026
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
- FRONTEO’s AI Engine Uncovers Novel Pancreatic Cancer Targets as Company Eyes Out-Licensing
July 24, 2025
- Interview: Mathematician Changing the Future of Drug Discovery (FRONTEO CTO)
March 25, 2025
BUSINESS
- Daiichi-AZ, Summit Team Up on Datroway Combo in Multiple Cancers
October 5, 2026
- Stargardt Diagnosis System Needs Bolstering as Treatment Nears: Expert
October 5, 2026
- Cheplapharm to Acquire MA for Kyowa Kirin’s 5-FU Products
October 5, 2026
- Nippon Kayaku Completes Buyout of Fuji’s Toyama Plant
October 5, 2026
- Teijin Finds “Best Owners” for Mucosolvan, Laxoberon
October 5, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…